Synthesis and evaluation of multitarget new 2-aminothiazole derivatives as potential anti-Alzheimer's agents
Özet
In this study, two diverse series of 2-aminothiazole-based multitarget compounds, one propenamide and the other propanamide derivatives, were designed and synthesized. Subsequently, their anticholinesterease and antioxidant (ORAC) activities were tested. Among them, compound 3e was the most potent acetylcholinesterase (AChE) inhibitor (AChE IC50 = 0.5 μM, butyrylcholinesterase [BChE] IC50 = 14.7 μM) and compound 9e was the most potent BChE inhibitor (AChE IC50 = 3.13 μM, BChE IC50 = 0.9 μM). Kinetic experiments showed that both compounds were mixed-type inhibitors. According to the anticholinesterease activity results, five compounds (3e, 4e, 5e, 9d, and 9e) were selected for further activity studies, all of which are dual cholinesterase inhibitors. Then, selected compounds were investigated in terms of their metal chelation activity. Moreover, their neuroprotective effects against H2O2-induced damage in the PC12 cell line were evaluated at 10 μM and the results showed that the neuroprotective effect of 3e was 53% compared with the reference ferulic acid (77%). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) results of selected compounds revealed that the compounds were noncytotoxic. Additionally, 3e was more effective in reducing lipopolysaccharides-induced interleukin-1β (IL-1β), IL-6, tumor necrosis factor-α (TNF-α), and nitric oxide (NO) production in the human monocyte derived from patient with acute monocytic leukemia cell line compared with other selected compounds. Finally, a molecular docking study was also performed.
Anahtar Kelimeler
- Scopus
- 27
- WoS
- 24
- OpenAlex
- 28
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Bardakkaya, Merve | |
| dc.contributor.author | Kilic, Burcu | |
| dc.contributor.author | Sagkan, Rahsan Ilıkcı | |
| dc.contributor.author | Aksakal, Fatma | |
| dc.contributor.author | Shakila, Shakila | |
| dc.contributor.author | Dogruer, Deniz S. | |
| dc.date.accessioned | 2026-10-27T23:47:46.012731282Z | |
| dc.date.available | 2026-10-27T23:47:46.012731282Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | In this study, two diverse series of 2-aminothiazole-based multitarget compounds, one propenamide and the other propanamide derivatives, were designed and synthesized. Subsequently, their anticholinesterease and antioxidant (ORAC) activities were tested. Among them, compound 3e was the most potent acetylcholinesterase (AChE) inhibitor (AChE IC50 = 0.5 μM, butyrylcholinesterase [BChE] IC50 = 14.7 μM) and compound 9e was the most potent BChE inhibitor (AChE IC50 = 3.13 μM, BChE IC50 = 0.9 μM). Kinetic experiments showed that both compounds were mixed-type inhibitors. According to the anticholinesterease activity results, five compounds (3e, 4e, 5e, 9d, and 9e) were selected for further activity studies, all of which are dual cholinesterase inhibitors. Then, selected compounds were investigated in terms of their metal chelation activity. Moreover, their neuroprotective effects against H2O2-induced damage in the PC12 cell line were evaluated at 10 μM and the results showed that the neuroprotective effect of 3e was 53% compared with the reference ferulic acid (77%). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) results of selected compounds revealed that the compounds were noncytotoxic. Additionally, 3e was more effective in reducing lipopolysaccharides-induced interleukin-1β (IL-1β), IL-6, tumor necrosis factor-α (TNF-α), and nitric oxide (NO) production in the human monocyte derived from patient with acute monocytic leukemia cell line compared with other selected compounds. Finally, a molecular docking study was also performed. | |
| dc.description.sponsorship | TUBITAK ULAKBIM | |
| dc.description.sponsorship | Türkiye Bilimsel ve Teknolojik Araştırma Kurumu, TÜBİTAK, (118S686) | |
| dc.description.sponsorship | Türkiye Bilimsel ve Teknolojik Araştırma Kurumu, TÜBİTAK | |
| dc.identifier.articlenumber | 2300054 | |
| dc.identifier.doi | 10.1002/ardp.202300054 | |
| dc.identifier.eissn | 1521-4184 | |
| dc.identifier.issn | 0365-6233 | |
| dc.identifier.issue | 8 | |
| dc.identifier.pmid | 37276369 | |
| dc.identifier.scopus | 2-s2.0-85161422377 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/kostu/10725 | |
| dc.identifier.volume | 356 | |
| dc.identifier.wos | WOS:000999398400001 | |
| dc.language.iso | en | |
| dc.publisher | John Wiley and Sons Inc | |
| dc.relation.ispartof | Archiv der Pharmazie | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | 2-aminothiazole | |
| dc.subject | Alzheimer's disease | |
| dc.subject | anti-inflammatory | |
| dc.subject | cholinesterase inhibitory activity | |
| dc.subject | neuroprotective effect | |
| dc.subject.classification | Chemistry, Medicinal | |
| dc.subject.classification | Chemistry, Multidisciplinary | |
| dc.subject.classification | Pharmacology & Pharmacy | |
| dc.subject.classification | Chemistry | |
| dc.subject.other | Acetylcholinesterase | |
| dc.subject.other | Alzheimer Disease | |
| dc.subject.other | Butyrylcholinesterase | |
| dc.subject.other | Cholinesterase Inhibitors | |
| dc.subject.other | Humans | |
| dc.subject.other | Molecular Docking Simulation | |
| dc.subject.other | Neuroprotective Agents | |
| dc.subject.other | Structure-Activity Relationship | |
| dc.subject.other | 2 aminothiazole derivative | |
| dc.subject.other | 3 (benzo[d][1,3]dioxol 5 yl) n [4 [[benzyl(methyl)amino]methyl]thiazol 2 yl]prop 2 enamide | |
| dc.subject.other | cholinesterase inhibitor | |
| dc.subject.other | donepezil | |
| dc.subject.other | ferulic acid | |
| dc.subject.other | interleukin 1beta | |
| dc.subject.other | interleukin 6 | |
| dc.subject.other | n [4 [[benzyl(methyl)amino]methyl]thiazol 2 yl] 3 (3,4 dimethoxyphenyl)prop 2 enamide | |
| dc.subject.other | n [4 [[benzyl(methyl)amino]methyl]thiazol 2 yl] 3 (4 benzylpiperazin 1 yl)propanamide | |
| dc.subject.other | n [4 [[benzyl(methyl)amino]methyl]thiazol 2 yl] 3 (4 methoxyphenyl)prop 2 enamide | |
| dc.subject.other | n [4 [[benzyl(methyl)amino]methyl]thiazol 2 yl] 3 [4 (4 fluorobenzyl)piperazin 1 yl]propanamide | |
| dc.subject.other | nitric oxide | |
| dc.subject.other | propionamide derivative | |
| dc.subject.other | tumor necrosis factor | |
| dc.subject.other | unclassified drug | |
| dc.subject.other | 2-aminothiazole | |
| dc.subject.other | cholinesterase | |
| dc.subject.other | neuroprotective agent | |
| dc.subject.other | acute monocytic leukemia cell line | |
| dc.subject.other | animal cell | |
| dc.subject.other | antioxidant activity | |
| dc.subject.other | Article | |
| dc.subject.other | chelation | |
| dc.subject.other | cholinesterase inhibition | |
| dc.subject.other | controlled study | |
| dc.subject.other | drug design | |
| dc.subject.other | drug screening | |
| dc.subject.other | drug synthesis | |
| dc.subject.other | human | |
| dc.subject.other | human cell | |
| dc.subject.other | IC50 | |
| dc.subject.other | in vitro study | |
| dc.subject.other | molecular docking | |
| dc.subject.other | MTT assay | |
| dc.subject.other | neuroprotection | |
| dc.subject.other | nonhuman | |
| dc.subject.other | PC12 cell line (pheochromocytoma) | |
| dc.subject.other | rat | |
| dc.subject.other | metabolism | |
| dc.subject.other | structure activity relation | |
| dc.title | Synthesis and evaluation of multitarget new 2-aminothiazole derivatives as potential anti-Alzheimer's agents | |
| dc.type | Article | |
| rdl.citation.openalex | 28 | |
| rdl.citation.scopus | 27 | |
| rdl.citation.wos | 24 | |
| rdl.department | Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Ankara, Turkiye | |
| rdl.department | Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Biruni University, İstanbul, Turkiye | |
| rdl.department | Department of Medical Biology, Faculty of Medicine, Uşak University, Uşak, Turkiye | |
| rdl.department | Department of Chemistry, Faculty of Science, Hacettepe University, Ankara, Turkiye | |
| rdl.department | Department of Analytical Chemistry, Faculty of Pharmacy, Kocaeli Health and Technology University, Kocaeli, Turkiye | |
| rdl.oa.status | hybrid | |
| rdl.oa.url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ardp.202300054 | |
| rdl.scopus.quartile | Q2 | |
| rdl.sdg | SDG03 | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | PUBMED | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) | |
| rdl.wos.index | Index Chemicus (IC) |

